Novartis drug cut death risk by 35 percent in gene mutation breast cancer
Saturday, October 20, 2018 - 09:50
in Health & Medicine
An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.